Latest innovations in molecular biology, genetics and cell biology have revolutionized the understanding of disease parthenogenesis and efforts related to discovery of novel disease biomarkers and drug targets, eventually leading to development of more effective medication with fewer side effects. A special focus of these cutting-edge approaches has been the field of leukemia and other blood cancers with discovery of many new cancer-causing genes and therapies directly targeting cancer cells and oncogenes. Acute Myeloid Leukemia (AML) has undergone major innovations in terms of early diagnosis, molecular sub-classification of the disease, prognostic stratification and new drug discovery, culminating into patient-tailored treatment of AML patients. This books provides an account of the biology and account of genetic basis of AML and their implication in clinic and research.
